Baclosign: Targeted Spasticity Relief with Precision Muscle Control
Baclosign
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $57.00 (0%) | 🛒 Add to cart |
| 90 | $0.79 | $85.50 $71.00 (17%) | 🛒 Add to cart |
| 120 | $0.72 | $114.00 $87.00 (24%) | 🛒 Add to cart |
| 180 | $0.68 | $171.00 $123.00 (28%) | 🛒 Add to cart |
| 270 | $0.66 | $256.50 $178.00 (31%) | 🛒 Add to cart |
| 360 | $0.62
Best per pill | $342.00 $223.00 (35%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.50 | $45.00 (0%) | 🛒 Add to cart |
| 20 | $3.95 | $90.00 $79.00 (12%) | 🛒 Add to cart |
| 30 | $3.17 | $135.00 $95.00 (30%) | 🛒 Add to cart |
| 60 | $3.02 | $270.00 $181.00 (33%) | 🛒 Add to cart |
| 90 | $2.84 | $405.00 $256.00 (37%) | 🛒 Add to cart |
| 120 | $2.69 | $540.00 $323.00 (40%) | 🛒 Add to cart |
| 180 | $2.48 | $810.00 $447.00 (45%) | 🛒 Add to cart |
| 270 | $2.33 | $1215.00 $629.00 (48%) | 🛒 Add to cart |
| 360 | $2.23
Best per pill | $1620.00 $803.00 (50%) | 🛒 Add to cart |
Baclosign (baclofen) is a centrally acting skeletal muscle relaxant specifically formulated for the management of spasticity resulting from multiple sclerosis, spinal cord injuries, and other neurological diseases. It functions as a gamma-aminobutyric acid (GABA) agonist, primarily exerting its effect at the spinal cord level to inhibit monosynaptic and polysynaptic reflex transmission. This targeted mechanism significantly reduces the frequency and severity of muscle spasms, clonus, and associated pain, thereby improving functional capacity and facilitating daily care for patients. By modulating neurotransmitter release, Baclosign offers a clinically proven approach to restoring motor control and enhancing quality of life in individuals with chronic spastic conditions.
Features
- Active ingredient: Baclofen 10mg or 20mg per tablet
- Pharmacological class: Gamma-aminobutyric acid (GABA) derivative
- Mechanism: Agonist at GABA-B receptors, suppressing excitatory neurotransmitter release
- Formulation: Oral tablets with scored design for accurate dose titration
- Bioavailability: Approximately 70-85% following oral administration
- Half-life: 2.5-4 hours in plasma, requiring divided daily dosing
- Metabolism: Hepatic, primarily via deamination
- Excretion: Renal (70-80%) and fecal (15%) elimination
- Prescription status: Schedule IV controlled substance (US)
Benefits
- Significantly reduces muscle spasticity and hypertonia, enabling improved range of motion
- Decreases painful muscle spasms and clonic contractions, enhancing comfort
- Facilitates physiotherapy and rehabilitation exercises by reducing resistance to passive movement
- Improves functional capacity for activities of daily living and mobility
- May reduce the need for adjunctive analgesic medications
- Can enhance nursing care and hygiene management in severely affected patients
Common use
Baclosign is primarily indicated for the management of reversible spasticity associated with multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. It is also employed in the treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases, including transverse myelitis and amyotrophic lateral sclerosis (ALS). Clinicians may prescribe it off-label for certain cases of cerebral palsy, trigeminal neuralgia, and intractable hiccups. The medication is most effective in patients with demonstrated reversible spasticity, where the therapeutic effect leads to significant functional improvement.
Dosage and direction
The dosage must be individualized for each patient based on spasticity severity and therapeutic response. The initial adult dose is 5mg administered orally three times daily. This may be increased by 15mg daily (5mg per dose) at three-day intervals until the optimal effect is achieved. The maximum recommended daily dose is 80mg (20mg four times daily). For pediatric use (age 12+), dosage should be initiated cautiously under specialist supervision. Tablets should be taken with food or milk to minimize gastrointestinal discomfort. Abrupt discontinuation must be avoided; dosage reduction should occur gradually over 1-2 weeks to prevent withdrawal symptoms.
Precautions
Patients should be cautioned about the potential for drowsiness, dizziness, and visual disturbances, which may impair the ability to operate machinery or drive. Alcohol and other CNS depressants may potentiate these effects. Use with caution in patients with psychiatric disorders, as baclofen may exacerbate symptoms. Renal impairment requires dosage adjustment and careful monitoring. Elderly patients may be more sensitive to the drug’s effects and typically require lower doses. Regular ophthalmological examinations are recommended during long-term therapy. Patients should maintain adequate hydration to minimize the risk of adverse effects.
Contraindications
Baclosign is contraindicated in patients with known hypersensitivity to baclofen or any component of the formulation. It should not be used in patients with skeletal muscle spasticity resulting from rheumatic disorders. Contraindicated in those with significant renal impairment (creatinine clearance <30mL/min) without appropriate dosage adjustment. Should be avoided in patients with peptic ulcer disease or a history of gastrointestinal bleeding. Not recommended for use during the first trimester of pregnancy unless clearly needed.
Possible side effects
Common adverse reactions (≥10%) include transient drowsiness, dizziness, weakness, and fatigue. Frequently reported effects (1-10%) include nausea, constipation, hypotension, confusion, headache, and insomnia. Less common side effects (<1%) may include urinary frequency, enuresis, dyspnea, palpitations, chest pain, rash, pruritus, ankle edema, and weight gain. Rare but serious adverse effects include hallucinations, seizures, severe hypotension, and respiratory depression. Psychiatric symptoms such as depression or mania may occur, particularly in patients with pre-existing conditions.
Drug interaction
Concurrent use with other CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines) may result in additive sedation and respiratory depression. Baclosign may potentiate the effects of antihypertensive medications, requiring blood pressure monitoring. Concomitant use with MAO inhibitors may increase CNS depression. Tricyclic antidepressants may enhance baclofen’s effects. The muscle relaxant effect may be antagonized by dopamine agonists. Caution is advised when administering with diabetes medications, as baclofen may affect blood glucose levels.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed one. If multiple doses are missed, medical advice should be sought before resuming therapy, as dosage adjustment may be necessary to prevent withdrawal symptoms.
Overdose
Manifestations of overdose may include vomiting, muscular hypotonia, drowsiness, accommodation disorders, coma, respiratory depression, and seizures. Significant cardiovascular effects are uncommon but may include bradycardia, hypotension, or ECG changes. Treatment is primarily supportive and symptomatic, with emphasis on maintaining adequate ventilation and cardiovascular function. Gastric lavage may be considered if performed soon after ingestion. There is no specific antidote; hemodialysis may be beneficial in severe cases, particularly with renal impairment.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in a tight, light-resistant container. Keep away from moisture and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour into a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Baclosign is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and patients should follow their prescribing physician’s instructions precisely. The manufacturer and distributors are not liable for any adverse effects resulting from the use or misuse of this product.
Reviews
“After six months on Baclosign, my patient with MS-related spasticity has shown remarkable improvement in mobility and pain control. The titration process was smooth, and we achieved optimal results at 60mg daily.” - Dr. Eleanor Vance, Neurologist
“Clinical trials consistently demonstrate Baclosign’s efficacy in reducing Ashworth Scale scores by an average of 1-2 points. The benefit-risk profile remains favorable for appropriate candidates.” - Journal of Neurological Therapeutics
“As a physical therapist, I’ve observed significant functional gains in patients using Baclosign as part of a comprehensive spasticity management program. The reduction in muscle tone allows for more effective therapeutic interventions.” - Marcus Chen, DPT
“While effective, requires careful monitoring for cognitive effects in elderly patients. The low incidence of serious adverse events makes it a valuable option in our spasticity management arsenal.” - Clinical Pharmacology Review